Paid Clinical Trials and Focus Groups by Location |
|
|
|
Conditions: Advanced Gastric Cancer; Gastro-esophageal Junction Cancer
Interventions: Drug: AUY922; Drug: Docetaxel or Irinotecan
Sponsor: Novartis Pharmaceuticals
Not yet recruiting - verified March 2010
Condition: Cytomegalovirus Infection
Interventions: Biological: Adoptive Cellular Therapy; Drug: Best available antiviral drug therapy
Sponsors: Cell Medica Ltd; Wellcome Trust; Choice Pharma Ltd; Commitum AB; BioAnaLab
Recruiting - verified February 2010
Condition: Coronary Artery Disease
Intervention: Device: Radi pressure wire (pressure wire assessment)
Sponsor: Southampton University Hospitals NHS Trust
Recruiting - verified October 2009
Condition: Psoriasis
Interventions: Drug: Ustekinumab/Methotrexate; Drug: Ustekinumab/Methotrexate
Sponsor: Janssen-Cilag International NV
Recruiting - verified February 2010
Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Not yet recruiting - verified January 2010
Conditions: Diabetes Mellitus, Type 2; Cardiovascular Diseases; Risk Factors
Interventions: Drug: Canagliflozin on background standard of care for diabetes; Drug: Placebo on background standard of care for diabetes
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; George Institute, Sydney, Australia
Recruiting - verified February 2010
Condition: Hepatitis C Virus
Interventions: Drug: BMS-650032; Drug: BMS-650032; Drug: BMS-650032; Drug: BMS-650032; Drug: Peginterferon Alfa-2a; Drug: Peginterferon Alfa-2a; Drug: Ribavirin; Drug: Ribavirin
Sponsor: Bristol-Myers Squibb
Recruiting - verified December 2009
Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: capecitabine; Drug: trastuzumab
Sponsor: Hoffmann-La Roche
Not yet recruiting - verified February 2010
Condition: Carcinoma, Renal Cell
Interventions: Drug: BIBF 1120; Drug: sunitinib
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: taspoglutide; Drug: placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified March 2010
Conditions: Influenza A Virus, H1N1 Subtype; Influenza B Virus; Influenza, Human; Influenza, Seasonal
Intervention: Drug: zanamivir aqueous solution
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Conditions: Ovarian Neoplasms; Peritoneal Neoplasms
Interventions: Drug: Placebo; Drug: BIBF 1120
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Arthritis, Psoriatic
Interventions: Drug: placebo; Drug: ustekinumab; Drug: ustekinumab; Drug: placebo; Drug: ustekinumab; Drug: ustekinumab; Drug: placebo; Drug: ustekinumab
Sponsor: Centocor, Inc.
Recruiting - verified February 2010
Condition: Malignant Melanoma
Interventions: Drug: RO5185426; Drug: dacarbazine
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Aclidinium bromide; Drug: Placebo
Sponsors: Almirall, S.A.; Forest Laboratories
Recruiting - verified March 2010
Condition: Glioblastoma
Interventions: Procedure: Radiotherapy; Procedure: Radiotherapy; Drug: BIBW2992; Drug: BIBW2992; Drug: Temozolomide
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Tiotropium 18mcg daily; Drug: Salmeterol 100mcg daily; Drug: Fluticasone 250mcg daily; Drug: Fluticasone 125mcg daily; Drug: Fluticasone 50mcg daily; Drug: Placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Conditions: Diabetes Mellitus, Type 2; Acute Coronary Syndrome
Interventions: Drug: Alogliptin; Drug: Placebo
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: INSULIN GLARGINE (HOE901); Drug: Insulin aspart; Drug: Insulin Glulisine
Sponsor: Sanofi-Aventis
Recruiting - verified March 2010
Condition: Glioblastoma
Interventions: Drug: Dasatinib; Drug: Lomustine
Sponsors: Bristol-Myers Squibb; European Organization for Research and Treatment of Cancer
Recruiting - verified December 2009
Conditions: Anemia; Chronic Kidney Disease
Intervention: Drug: darbepoetin alfa
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Endometrial Cancer
Interventions: Drug: BN83495; Drug: Megestrol Acetate (MA)
Sponsor: Ipsen
Recruiting - verified February 2010
Condition: Alzheimer's Disease
Interventions: Drug: LY2062430; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006); Drug: Sorafenib (Nexavar, BAY43-9006) + Erlotinib, Tarceva
Sponsors: Bayer; Onyx Pharmaceuticals; OSI Pharmaceuticals; Hoffmann-La Roche
Recruiting - verified March 2010
Condition: Toxicity
Intervention: Other: Pharmacogenomic whole blood sampling
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified February 2010
Condition: Alzheimer Disease
Interventions: Drug: RO5313534; Drug: RO5313534; Drug: RO5313534; Drug: Placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Endometrial Cancer
Interventions: Drug: Ixabepilone; Drug: Doxorubicin; Drug: Paclitaxel
Sponsor: Bristol-Myers Squibb
Recruiting - verified March 2010
Condition: Ovarian Cancer
Interventions: Drug: MORAb-003 (farletuzumab); Drug: MORAb-003 (farletuzumab); Drug: 0.9% Saline
Sponsor: Morphotek
Recruiting - verified October 2009
Condition: Chronic Kidney Disease
Intervention: Other: OBSERVATIONAL - NO INTERVENTON
Sponsor: Amgen
Recruiting - verified February 2010
Conditions: Metastatic; Colorectal Cancer
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin); Drug: Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)
Sponsors: Bayer; Onyx Pharmaceuticals
Recruiting - verified February 2010
Condition: Acute Coronary Syndrome
Interventions: Drug: Apixaban; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Pfizer; Duke University
Recruiting - verified October 2009
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: OFC Infusion; Drug: FC infusion
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: taspoglutide; Drug: placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Pulmonary Hypertension
Interventions: Drug: Riociguat (BAY63-2521); Drug: Riociguat (BAY63-2521); Drug: Placebo
Sponsor: Bayer
Recruiting - verified February 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra]; Drug: methotrexate; Drug: placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Pulmonary Hypertension
Interventions: Drug: Riociguat (BAY63-2521); Drug: Placebo
Sponsor: Bayer
Recruiting - verified February 2010
Conditions: Atherosclerosis; Cardiovascular Disease; Coronary Heart Disease; CV Risk
Interventions: Drug: Darapladib; Drug: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Conditions: Soft Tissue Sarcomas; Translocation-Related Sarcomas (TRS)
Intervention: Drug: Trabectedin, ET 743 and Yondelis
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; PharmaMar
Recruiting - verified February 2010
Conditions: Acute Lung Injury; Acute Respiratory Distress Syndrome
Intervention: Drug: Interferon Beta
Sponsor: Faron Pharmaceuticals Ltd
Recruiting - verified March 2009
Condition: Ulcerative Colitis
Interventions: Drug: CP- 690 550; Drug: CP- 690 550; Drug: CP- 690 550; Drug: CP- 690 550; Other: placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Gastrointestinal Stromal Tumor (GIST)
Interventions: Drug: Nilotinib (AMN107); Drug: imatinib (STI571)
Sponsor: Novartis Pharmaceuticals
Recruiting - verified February 2010
Condition: Leukemia
Interventions: Drug: Dasatinib; Drug: Dasatinib
Sponsor: Bristol-Myers Squibb
Recruiting - verified February 2010
Condition: Idiopathic Pulmonary Fibrosis
Intervention: Drug: ambrisentan or sugar pill
Sponsor: Gilead Sciences
Recruiting - verified March 2010
Condition: Soft Tissue Sarcoma
Intervention: Drug: PAZOPANIB
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: ofatumumab (GSK1841157) infusion; Drug: chlorambucil, tablets
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Locally Advanced and/or Metastatic Renal Cell Carcinoma
Interventions: Drug: Sunitinib; Drug: Pazopanib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Conditions: Carcinoma, Renal Cell; Adenocarcinoma, Renal Cell; Nephroid Carcinoma; Carcinoma, Hypernephroid
Interventions: Drug: bevacizumab, RAD001(Everolimus); Drug: bevacizumab, interferon alfa-2a
Sponsors: Novartis Pharmaceuticals; Roche Pharma AG
Recruiting - verified March 2010
Condition: Thyroid Cancer
Interventions: Drug: XL184; Drug: Placebo
Sponsor: Exelixis
Recruiting - verified March 2010
Conditions: Hormone Refractory Prostate Cancer; Bone Metastases
Interventions: Drug: Alpharadin (Radium-223); Drug: Placebo
Sponsor: Algeta ASA
Recruiting - verified March 2009
Condition: Prostatic Neoplasms
Interventions: Drug: Prednisone; Drug: sunitinib; Drug: Placebo; Drug: Prednisone
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Kidney Neoplasms
Interventions: Drug: Axitinib (AG-013736); Drug: Sorafenib
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: Lymphoma; Neoplasms
Intervention: Drug: JNJ-26481585
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Janssen Pharmaceutica N.V., Belgium
Recruiting - verified February 2010
Condition: Alzheimer Disease
Interventions: Drug: bapineuzumab; Drug: placebo
Sponsor: Wyeth
Recruiting - verified February 2010
Condition: Alzheimer Disease
Interventions: Drug: bapineuzumab; Drug: placebo
Sponsor: Wyeth
Recruiting - verified February 2010
Condition: Chronic Bronchitis
Interventions: Drug: Avelox (Moxifloxacin, BAY12-8039); Drug: Amoxicillin clavulanic acid
Sponsor: Bayer
Recruiting - verified March 2010
Condition: Coronary Heart Disease
Interventions: Drug: dalcetrapib; Drug: Placebo; Drug: Evidence-based medical care for Acute Coronary Syndrome
Sponsor: Hoffmann-La Roche
Recruiting - verified March 2010
Condition: Sarcoma
Interventions: Drug: bevacizumab [Avastin]; Drug: Standard chemotherapy
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Ocular Safety
Intervention: Drug: Observational Study
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Conditions: Advanced Non-Small Cell Lung Cancer; Transitional Cell Carcinoma; Soft Tissue Sarcoma; Gastric/Esophageal Adenocarcinoma; Pancreatic Cancer Including Ampulla of Vater
Interventions: Drug: brivanib; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Condition: Neoplasms
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
Sponsors: Bayer; ICON Clinical Research
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: ZD4054; Drug: Luteinising hormone-releasing hormone analogue (LHRHa); Drug: Megace; Drug: Estradiol; Drug: Prednisolone; Drug: Ketoconazole; Drug: Docetaxel
Sponsor: AstraZeneca
Recruiting - verified February 2010
Condition: Sepsis
Interventions: Drug: Drotrecogin alfa (activated); Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Condition: Venous Thromboembolism
Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939); Drug: Enoxaparin
Sponsors: Bayer; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified March 2010
Condition: Inflammatory Breast Cancer
Interventions: Drug: lapatinib (Tykerb); Drug: pazopanib (GW786034); Drug: Pazopanib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Conditions: Chronic Kidney Disease; Dialysis; Hyperphosphatemia
Interventions: Drug: MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE®); Drug: Another Phosphate binder
Sponsor: Mitsubishi Tanabe Pharma Corporation
Recruiting - verified February 2010
Condition: Moderate Risk of CVD
Interventions: Drug: Aspirin (Acetylsalicylic acid, BAYE4465); Drug: Placebo
Sponsor: Bayer
Recruiting - verified February 2010
Condition: Colorectal Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Xeloda
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Taxane-based chemotherapy
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Conditions: Lymphoma; Neutropenia; Psychosocial Effects of Cancer and Its Treatment; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: amoxicillin-clavulanate potassium; Drug: ciprofloxacin; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsor: Clatterbridge Centre for Oncology
Recruiting - verified May 2007
Conditions: Atrial Fibrillation; Atrial Flutter
Interventions: Drug: warfarin; Drug: apixaban
Sponsor: Bristol-Myers Squibb
Recruiting - verified October 2009
Conditions: Fabry Disease; Cerebrovascular Accident
Intervention: Other: No intervention
Sponsors: University of Rostock; Shire Human Genetic Therapies, Inc.
Recruiting - verified February 2010
Conditions: Mitral Regurgitation; Coronary Artery Disease
Interventions: Procedure: Mitral annuloplasty; Procedure: Coronary Artery Bypass Graft Surgery
Sponsors: Imperial College London; Department of Health, United Kingdom; British Heart Foundation; British Medical Association; Hammersmith Hospitals NHS Trust; St Mary's NHS Trust; King's College Hospital NHS Trust; Glasgow Royal Infirmary; Golden Jubilee National Hospital; University Hospitals, Leicester; Nottingham University Hospitals NHS Trust; Medical University of Silesia; Papworth Hospital; Central Manchester University Hospitals NHS Foundation Trust; United Bristol Healthcare NHS Trust; Blackpool, Flyde and Wyre Hospitals NHS Foundation Trust; Oxford Radcliffe Hospitals NHS Trust
Recruiting - verified March 2010
Condition: Kidney Neoplasms
Interventions: Drug: Sunitinib malate; Other: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Liver Cancer
Interventions: Drug: capecitabine; Other: clinical observation; Procedure: adjuvant therapy
Sponsor: Southampton University Hospitals NHS Trust
Recruiting - verified March 2008
Conditions: Heart Failure; Anemia; Cardiovascular Disease; Ventricular Dysfunction; Congestive Heart Failure
Interventions: Drug: Darbepoetin alfa; Drug: Placebo
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Endocrine Tumors
Interventions: Drug: lanreotide (Autogel formulation); Other: Placebo
Sponsor: Ipsen
Recruiting - verified March 2010
Condition: Non Hodgkin Lymphoma
Interventions: Drug: enzastaurin; Drug: placebo
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Condition: Epilepsy, Partial
Interventions: Drug: Pregabalin; Drug: Lamotrigine
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Heart Failure
Interventions: Drug: Eplerenone; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Sarcoma
Interventions: Biological: dactinomycin; Drug: busulfan; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: melphalan; Drug: vincristine sulfate; Procedure: autologous hematopoietic stem cell transplantation; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: University Hospitals, Leicester; National Cancer Institute (NCI); Children's Cancer and Leukaemia Group; Societe Francaise Oncologie Pediatrique; European Organization for Research and Treatment of Cancer; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria; Swiss Group for Clinical Cancer Research; EBMT Solid Tumors Working Party; Children's Oncology Group
Recruiting - verified March 2010
All Locations ... United Kingdom » ... England » ... Glasgow 
Login/sign up for more tools for finding clinical trials. Login/Sign up Here
